Current concepts in managing pelvic inflammatory disease

Current Opinion in Infectious Diseases

Volumn 23, Issue 1, 2010, Pages 83-87

  Judlin, Philippe ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Bacterial vaginosis; Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; Pelvic inflammatory disease; Salpingitis

Indexed keywords

AZITHROMYCIN; CEFOXITIN; CEFTRIAXONE; DOXYCYCLINE; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GONORRHEA; HUMAN; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; NONHUMAN; OUTPATIENT CARE; PATHOGENESIS; PELVIC INFLAMMATORY DISEASE; REVIEW; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; VAGINITIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE;

EID: 74249105447     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328334de21     Document Type: Review

References (36)

1. Centers for Diseases Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2006. Morb Mortal Wkly Rep 2006; 55(RR11):1-94.
2. Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2007; 18:662-666. (Pubitemid 351738895)
3. Royal College of Obstetricians and Gynaecologists. Management of acute pelvic inflammatory disease. Green-top Guideline No. 32, Nov 2008. Available on: http://www.rcog.org.uk/search/node/green-top+guideline.
4. Boukes FS, Dekker JH, Wiersma TJ, et al. Summary of the practice guideline 'Pelvic inflammatory disease' (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2007; 151:753-756.
5. Sørbye IK, Jerve F, Staff AC. Reduction of hospitalized women with pelvic inflammatory disease in Oslo over the past decade. Acta Obstet Gynecol Scand 2005; 84:290-296.
6. Simms I, Eastick K, Mallinson H, et al. Association between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol 2003; 56:616-618. (Pubitemid 36976362)
7. Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis 2008; 21:65-69.
8. Ness RB, Soper DE, Holey RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929-937.
9. Saini S, Gupta N, Batra G, et al. Role of anaerobes in acute pelvic inflammatory disease. Indian J Med Microbiol 2003; 21:189-192.
10. Ness RB, Kip KE, Hillier SL, et al. A cluster of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005; 162:585-590.
11. Livengood CH. Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol 2009; 2:28-37.
12. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-1911.
13. Haggerty CL, Totten PA, Ferris M, et al. Clinical characteristics of bacterial vaginosis among women testing positive for fastidious bacteria. Sex Transm Infect 2009; 85:242-248.
14. Hebb JK, Cohen CR, Astete SG, et al. Detection of novel organisms associated with salpingitis, by use of 16SrDNA polymerase chain reaction. J Infect Dis 2004; 190:2109-2120.
15. Ross JDC, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implication for screening, testing and treatment. Sex Transm Infect 2006; 82:269-271.
16. Judlin P. Genital mycoplasmas. Gynecol Obstet Fertil 2003; 31:954-955.
17. Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol 2006; 2006:30184.
18. Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009; 48:41-47.
19. Haggerty CL, Totten PA, Astete SG, et al. Failure of cefoxitin and doxycyclineto eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex Transm Dis 2008; 84:338-342.
20. Ross JD, Cronje HS, Paszkowski T, et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Inf 2006; 82:446-451.
21. Jakopec I, Borgen K, Aavitsland P. The epidemiology of gonorrhoeae in Norway, 1993-2007: past victories, future challenges. BMC Infect Dis 2009; 9:33
22. ESSTI. Sexually transmitted infections in Europe. Health protection Agency, 2007. No.2. http://www.cdc.gov/std/GISP2007/GISPSurv/Supp2007 Short.pdf.
23. Tapsall JW, Shultz TR, Lovett R, Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoeae. Med J Aust 1992; 156:143.
24. Gallay A, Bouyssou-Michel A, Lassau F, et al. Neisseria gonorrhoeae infections in France in 2006: significant progression in women and persistent increase of ciprofloxacin resistance. Bull Epidemiologique Hebdomadaire 2008; N 5-6:35-36.
25. Centers for Diseases Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007; 56:332-336.
26. Agence Francaise de Securite Sanitaire des Produits de Sante (AFFSAPS). Empirical antimicrobial treatment for non complicated uretritis and cervicitis. 2005 with actualisation in March 2009. www.afssaps.fr.
27. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009; 22:87-91.
28. Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64:353-358.
29. Savaris RF, Texeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol 2007; 110:53-60.
30. Stass H, Kubitza D, Aydeniz B, et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102:132-136.
31. Judlin P, Thiebaugeorges O. Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. Eur J Obstet Gynecol Reprod Biol 2009; 145:177-179.
32. EMEA. Press Release. European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines. 24 July 2008. www.emea.europa.eu.
33. Judlin PG, Thiebaugeorges O. Pelvic inflammatory diseases. Gynecol Obstet Fertil 2009; 37:172-182.
34. Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44:953-960.
35. Altunyurt S, Denir N, Posaci C. A randomised controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Gynecol Obstet Reprod Biol 2003; 107:81-84.
36. Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999; 181:1374-1381.